{"id":"W3174459433","doi":"10.1016/j.eucr.2021.101762","title":"Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Urology Case Reports","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; University of British Columbia; Surrey Place Centre; Surrey Memorial Hospital","funders":"Canadian Institutes of Health Research; Bladder Cancer Canada; Astellas Pharma Canada; Merck; Janssen Pharmaceuticals; AstraZeneca","keywords":"Durvalumab; Medicine; Urothelial cancer; Immune checkpoint; Bladder cancer; Tremelimumab; Metastatic Urothelial Carcinoma; Avelumab; Oncology; Immunotherapy; Disease; Missense mutation; Cancer research; Cancer; Internal medicine; Urothelial carcinoma; Mutation; Nivolumab; Ipilimumab; Gene; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005949493,0.0002208728,0.0005788183,0.0001626479,0.0001254976,0.000005647744,0.00002887205,0.0001379692,0.0003267959],"category_scores_gemma":[0.0002538023,0.000210813,0.0002639003,0.0002253509,0.00005235665,0.00003742155,0.0001257536,0.000204735,0.00002269195],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001444841,"about_ca_system_score_gemma":0.00185925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001192131,"about_ca_topic_score_gemma":0.00006649287,"domain_scores_codex":[0.9978124,0.0001300126,0.0009577867,0.0004959572,0.0002619826,0.0003418886],"domain_scores_gemma":[0.9987699,0.00007458036,0.0001990049,0.0005751834,0.000145003,0.0002362744],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00154284,0.0002177962,0.0113957,0.00004967492,0.0003292038,0.4971788,0.002024968,0.000002669937,0.4834418,0.000002294438,0.00007647042,0.003737802],"study_design_scores_gemma":[0.003243869,0.0008676316,0.08572657,0.00006216611,0.0004118793,0.2974085,0.0004507141,0.000004237091,0.5604908,0.00003795609,0.05098572,0.0003100147],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954398,0.0007978537,0.0001015482,0.0007760702,0.0008406578,0.000435559,0.0000161913,0.00004547184,0.001546881],"genre_scores_gemma":[0.9944674,0.000001592555,0.004069892,0.000613094,0.0001002249,0.00005941799,0.00003995663,0.00003887268,0.0006095376],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1997703,"threshold_uncertainty_score":0.8596703,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02128113715824269,"score_gpt":0.277644438413306,"score_spread":0.2563633012550633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}